BD partners with US government to expand domestic manufacturing of medical consumables
BDX•BD plans to invest $19 billion over several years, including $3 billion to expand US manufacturing, targeting about 5 billion additional consumables annually and a roughly 80% domestic supply share. The agreement calls for all BD needles used in the US to be made domestically with American-made steel and offers potential relief from future Section 232 tariffs on covered products, subject to scope and milestone delivery.
1. Manufacturing expansion
BD entered a partnership with the US government to expand domestic manufacturing of essential medical consumables. Its planned investment totals $19 billion over several years, including $3 billion for US manufacturing expansion, with targeted output rising by about 5 billion consumables a year and BD’s domestically supplied share reaching roughly 80%.
2. Needles and tariffs
The agreement calls for 100% of BD needles used in the US to be made domestically using American-made steel. It offers potential relief from future Section 232 tariffs on covered products, subject to final scope and milestone delivery.
